INCHEON Korea April 24 2017 Samsung Bioepis Co. Ltd. today announced that the U.S. Food and Drug Administration FDA has approved RENFLEXIS infliximababda a biosimilar referencing RemicadeÂi infliximab across all eligible indications. In the US RENFLEXIS ...
↧